We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
Read MoreHide Full Article
Stryker Corporation (SYK - Free Report) is well poised for growth backed by robust robotic-arm assisted surgery platform — Mako and diversified product portfolio. However, pricing pressure remains a headwind.
Shares of the company have gained 43.5% compared with the industry’s 23.3% rally on a year-to-date basis. Meanwhile, the S&P 500 Index has surged 56% in the same time frame.
Stryker, with a market capitalization of $96.62 billion, is one of the world’s largest medical device companies operating in the orthopedic market. It anticipates earnings to improve 9.6% in the next five years. Moreover, it has a trailing four-quarter earnings surprise of 18.8%, on average.
Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).
What’s Deterring the Stock?
An unfavorable pricing environment poses a persistent threat to Stryker’s core businesses. In fact, pricing in fourth-quarter 2020 had an impact of 0.8% on the top line. Hence, pricing pressure continues to weigh on its performance.
What’s Favoring Growth?
Mako is Stryker’s robotic-arm assisted surgery platform. The company continues to witness strong demand for Mako and healthy order book, courtesy of the platform’s unique features, despite financial constraints stemming from the COVID-19 pandemic. This, in turn, positions it well to sustain momentum in robot sales and recon share market gains. For 2021, the company’s Mako order book remains solid, and is in sync with its aim of continuous share gains in both hips and knees.
During 2020, the company’s Mako install base saw 33% growth, and beat another milestone with more than 100 robots sold and installed in fourth-quarter 2020. Thereby, it continues to focus on the expansion of Mako.
Additionally, Stryker has a diversified product portfolio. Its wide range of products shields the company against any significant sales shortfall during economic turmoil. Its significant exposure in robotics, Artificial Intelligence for health care and Medical Mechatronics has provided the company with a competitive edge in the MedTech space. Stryker’s portfolio includes products like Hip, Knee and Mako robotic-arm assisted surgeries.
During fourth-quarter 2020, the company unveiled the ASC (Ambulatory Surgery Center) sales model that leverages its portfolio by offering end-to-end solutions to cater to the rising demand and shifts regarding outpatient setting. Per management, the company’s sustained support for customers and focus on innovation will position it well for growth, as the pandemic eventually subsides.
Apart from these, Stryker has been one of the earliest adopters of the 3D printing technology. The company’s FDA-approved Tritanium TL Curved Posterior Lumbar Cage is a 3D-printed interbody fusion cage intended for use as an aid in lumbar fixation.
Estimates Trend
For 2021, the Zacks Consensus Estimate for revenues is pegged at $17.07 billion, indicating an improvement of 18.9% from the previous year. The same for earnings stands at $9.05, suggesting growth of 21.8% from the year-ago reported figure.
AmerisourceBergen’s long-term earnings growth rate is expected at 11.4%.
DENTSPLY SIRONA’s long-term earnings growth rate is estimated at 20%.
Cantel Medical’s long-term earnings growth rate is estimated at 19%.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Image: Bigstock
Here's Why You Should Retain Stryker (SYK) Stock Right Now
Stryker Corporation (SYK - Free Report) is well poised for growth backed by robust robotic-arm assisted surgery platform — Mako and diversified product portfolio. However, pricing pressure remains a headwind.
Shares of the company have gained 43.5% compared with the industry’s 23.3% rally on a year-to-date basis. Meanwhile, the S&P 500 Index has surged 56% in the same time frame.
Stryker, with a market capitalization of $96.62 billion, is one of the world’s largest medical device companies operating in the orthopedic market. It anticipates earnings to improve 9.6% in the next five years. Moreover, it has a trailing four-quarter earnings surprise of 18.8%, on average.
Let’s take a closer look at the factors that substantiate the company’s Zacks Rank #3 (Hold).
What’s Deterring the Stock?
An unfavorable pricing environment poses a persistent threat to Stryker’s core businesses. In fact, pricing in fourth-quarter 2020 had an impact of 0.8% on the top line. Hence, pricing pressure continues to weigh on its performance.
What’s Favoring Growth?
Mako is Stryker’s robotic-arm assisted surgery platform. The company continues to witness strong demand for Mako and healthy order book, courtesy of the platform’s unique features, despite financial constraints stemming from the COVID-19 pandemic. This, in turn, positions it well to sustain momentum in robot sales and recon share market gains. For 2021, the company’s Mako order book remains solid, and is in sync with its aim of continuous share gains in both hips and knees.
During 2020, the company’s Mako install base saw 33% growth, and beat another milestone with more than 100 robots sold and installed in fourth-quarter 2020. Thereby, it continues to focus on the expansion of Mako.
Additionally, Stryker has a diversified product portfolio. Its wide range of products shields the company against any significant sales shortfall during economic turmoil. Its significant exposure in robotics, Artificial Intelligence for health care and Medical Mechatronics has provided the company with a competitive edge in the MedTech space. Stryker’s portfolio includes products like Hip, Knee and Mako robotic-arm assisted surgeries.
During fourth-quarter 2020, the company unveiled the ASC (Ambulatory Surgery Center) sales model that leverages its portfolio by offering end-to-end solutions to cater to the rising demand and shifts regarding outpatient setting. Per management, the company’s sustained support for customers and focus on innovation will position it well for growth, as the pandemic eventually subsides.
Apart from these, Stryker has been one of the earliest adopters of the 3D printing technology. The company’s FDA-approved Tritanium TL Curved Posterior Lumbar Cage is a 3D-printed interbody fusion cage intended for use as an aid in lumbar fixation.
Estimates Trend
For 2021, the Zacks Consensus Estimate for revenues is pegged at $17.07 billion, indicating an improvement of 18.9% from the previous year. The same for earnings stands at $9.05, suggesting growth of 21.8% from the year-ago reported figure.
Stocks to Consider
Some better-ranked stocks from the broader medical space include AmerisourceBergen Corporation , DENTSPLY SIRONA Inc. (XRAY - Free Report) and Cantel Medical Corp. , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AmerisourceBergen’s long-term earnings growth rate is expected at 11.4%.
DENTSPLY SIRONA’s long-term earnings growth rate is estimated at 20%.
Cantel Medical’s long-term earnings growth rate is estimated at 19%.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>